

Special Issue

Amaryllidaceae Alkaloids

Message from the Guest Editors

Since galanthamine was approved by the FDA in 2001 for the palliative treatment of Alzheimer's disease, the interest in Amaryllidaceae alkaloids and their synthetic derivatives has grown considerably. A variety of biological and pharmacological properties have been reported for this group of compounds, which has stimulated research activity even more. Recently, the threshold of 600 molecules isolated and characterized from this plant family was passed, and we think this is an opportune moment for all the groups working with these particular natural products to explain their recent research in the field.

Guest Editors

Prof. Dr. Jaume Bastida


Group of Natural Products, Faculty of Pharmacy, University of Barcelona, Av. Joan XXIII, 27-31, 08028 Barcelona, Spain

Prof. Dr. Strahil Berkov

Group of Chemoecology and Natural Products, Institute of Biodiversity and Ecosystem Research, Bulgarian Academy of Sciences, 23 Acad. Georgi Bonchev Street, 1113 Sofia, Bulgaria

Deadline for manuscript submissions

closed (31 December 2020)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/29568

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).